Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung CancerAlexander Drilon, Vivek Subbiah, Jyoti D. Patel et al.|New England Journal of Medicine|2020Cited by 835
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic CholangiocarcinomaLipika Goyal, John Bridgewater, Funda Meric‐Bernstam et al.|New England Journal of Medicine|2023Cited by 530
Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor EraPhilippe A. Cassier, Peter Hohenberger|Clinical Cancer Research|2012Cited by 233
Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumorsYonina R. Murciano‐Goroff, Joshua K. Sabari, Rebecca S. Heist et al.|Cancer Research|2023Cited by 37
Reasons for acceptance and refusal of early palliative care in patients included in early-phase clinical trials in a regional comprehensive cancer centre in France: protocol for a qualitative studyGisèle Chvetzoff, Véronique Christophe, Magali Girodet et al.|BMJ Open|2022Cited by 5